REG - EKF Diagnostics Hldg - AGM statement & positive Q1 trading update

EKF Diagnostics HoldingsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260519:nRSS7901Ea&default-theme=true

RNS Number : 7901E  EKF Diagnostics Holdings PLC  19 May 2026

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

AGM Statement

& Positive Q1 Trading update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, provides an update to shareholders ahead of its Annual General
Meeting ('AGM') today at Harwood Capital LLP, 6 Stratton Street, Mayfair,
London W1J 8LD at 11.00 am.

 

Executive Chair's AGM statement

We are very pleased that trading to date for the year ended 31 December 2026
("FY 2026") remains in-line with management expectations. As usual, we will
provide an unaudited trading update for first six months of the current
financial year ("H1 2026") at the end of July.

 

The completion of the first year of our Five-Year Strategic Development plan
has firmly re-established the business with a simplified product offering, a
greater commercial focus on the areas of strategic importance and an expanded
marketing team to drive further organic growth.

 

Operational cash generation continues to be very strong alongside the
continued internal investment for growth and the ongoing share buyback
programme. Cash position as of 8 May is £15.0m, with £2.1m held by our
Russian subsidiary and subject to regulatory restrictions, and we will
continue to invest in areas that will further build on our growth strategy,
and deliver long term shareholder value.

 

Commercial traction for Hematology remains strong with good ongoing instrument
placement and increased consumable pull-through as expected. Within the Life
Sciences division, β-HB sales have performed above management expectations
and the pipeline and prospects for our contract fermentation services
continues to grow showing continued steady improvement.

 

We remain excited about the prospects for the business and are on track to
deliver growth at the revenue and adjusted EBITDA(1) levels for FY 2026
in-line with market expectations(2).

 

(1)adjusted earnings before interest, tax, depreciation and amortisation,
share-based payments and exceptional items

²Management understands consensus revenue and Adjusted EBITDA forecasts for
FY 2026 to be £54.6m and £13.6m respectively.

 

 EKF Diagnostics Holdings plc                                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Gavin Jones, Chief Executive Officer         via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)                          Tel: +44 (0)20 7496 3000
 Phil Davies / Patrick Weaver

 Walbrook PR Limited                  Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings        Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMAKFBPPBKDCPD



            Copyright 2019 Regulatory News Service, all rights reserved